Mauna Kea Technologies : 2021: the year of lift-off
>Early publication confirms recovery - On the sidelines of our forum, Mauna Kea Technologies reported its estimated revenue for Q4 2020, something the company has done for several quarters due to the volatility in its operations resulting from the COVID-19 crisis. The least we can say is that business levels are good – indeed very good. The company sees Q4 growth coming in between 30% and 36% to € 2.2m-2.3m, a quarterly performance unprecedented since Q2 2016, when th...Mauna Kea Technologies is a global medical device company based in France. Co. is focused on innovations in the field of endomicroscopy (microscopic imaging during endoscopy procedures). Co. is predominately active in the advent of optical biopsy. Co. researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Co.'s flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Co. has marketing authorizations in Thailand, United Kingdom, U.S., Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.